Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.

Brown NA, Elenitoba-Johnson KSJ.

Curr Opin Pulm Med. 2018 May;24(3):281-286. doi: 10.1097/MCP.0000000000000470. Review.

PMID:
29470255
2.

Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.

Tran G, Huynh TN, Paller AS.

J Am Acad Dermatol. 2018 Mar;78(3):579-590.e4. doi: 10.1016/j.jaad.2017.09.022. Epub 2017 Oct 26. Review.

PMID:
29107340
3.

MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.

Novosad O, Skrypets T, Pastushenko Y, Titorenko I, Martynchyk A, Skachkova O, Inomistova M, Gorbach A, Khranovska N, Kryachok I.

Klin Onkol. Spring 2018;31(2):130-136. doi: 10.14735/amko2018130.

PMID:
29708356
4.

Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.

Mourah S, How-Kit A, Meignin V, Gossot D, Lorillon G, Bugnet E, Mauger F, Lebbe C, Chevret S, Tost J, Tazi A.

Eur Respir J. 2016 Jun;47(6):1785-96. doi: 10.1183/13993003.01677-2015. Epub 2016 Apr 13.

5.

Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.

Egeler RM, Katewa S, Leenen PJ, Beverley P, Collin M, Ginhoux F, Arceci RJ, Rollins BJ; Steering Committee of the Nikolas Symposium.

Pediatr Blood Cancer. 2016 Oct;63(10):1704-12. doi: 10.1002/pbc.26104. Epub 2016 Jun 17. Review.

PMID:
27314817
6.

Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.

Kobayashi M, Tojo A.

Cancer Sci. 2018 Dec;109(12):3707-3713. doi: 10.1111/cas.13817. Epub 2018 Oct 30. Review.

7.

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW.

Blood. 2014 Nov 6;124(19):3007-15. doi: 10.1182/blood-2014-05-577825. Epub 2014 Sep 8.

8.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Chakraborty R, Sengal AG, Bellanné-Chantelot C, Thomas C, Moreau A, Fraitag S, Allen CE, Donadieu J, Emile JF.

Mol Cancer. 2017 Jul 6;16(1):115. doi: 10.1186/s12943-017-0690-z.

9.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O.

Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13.

10.

B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.

Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J, Geissmann F.

PLoS One. 2012;7(4):e33891. doi: 10.1371/journal.pone.0033891. Epub 2012 Apr 10. Erratum in: PLoS One. 2012;7(6). doi:10.1371/annotation/74a67f4e-a536-4b3f-a350-9a4c1e6bebbd. Mian, Sophie [corrected to Mian, Syed].

11.

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update.

Harmon CM, Brown N.

Arch Pathol Lab Med. 2015 Oct;139(10):1211-4. doi: 10.5858/arpa.2015-0199-RA. Review.

PMID:
26414464
12.

Genomic Alterations in Langerhans Cell Histiocytosis.

Rollins BJ.

Hematol Oncol Clin North Am. 2015 Oct;29(5):839-51. doi: 10.1016/j.hoc.2015.06.004. Review.

PMID:
26461146
13.

Somatic activating ARAF mutations in Langerhans cell histiocytosis.

Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovée JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ.

Blood. 2014 May 15;123(20):3152-5. doi: 10.1182/blood-2013-06-511139. Epub 2014 Mar 20.

PMID:
24652991
14.

Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.

Allen CE, Parsons DW.

Hematology Am Soc Hematol Educ Program. 2015;2015:559-64. doi: 10.1182/asheducation-2015.1.559. Review.

PMID:
26637772
15.

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

Abla O, Weitzman S.

Hematology Am Soc Hematol Educ Program. 2015;2015:565-70. doi: 10.1182/asheducation-2015.1.565.

PMID:
26637773
16.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J.

J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.

17.

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M.

Blood. 2017 Jul 13;130(2):167-175. doi: 10.1182/blood-2016-12-757823. Epub 2017 May 16.

18.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

19.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.

PMID:
24982505
20.

BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.

Varga E, Korom I, Polyánka H, Szabó K, Széll M, Baltás E, Bata-Csörgő Z, Kemény L, Oláh J.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1205-11. doi: 10.1111/jdv.12792. Epub 2014 Oct 28.

PMID:
25351766

Supplemental Content

Support Center